Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10389540 | 0.98 | CHRM2 (0.43) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL262052 | 0.98 | CHRM2 (0.43) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL12948024 | 0.98 | CHRM2 (0.43) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL10389542 | 0.98 | CHRM2 (0.43) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL27265137 | 0.98 | CHRM2 (0.43) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL23921599 | 0.93 | CHRM2 (0.47) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL7079357 | 0.93 | CHRM2 (0.47) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL8384596 | 0.93 | CHRM2 (0.47) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL7191976 | 0.93 | CHRM2 (0.47) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL2693326 | 0.93 | CHRM2 (0.47) | SLC6A2SLC6A4SMN1; SMN2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-10-02 | — | — | US | disclosed |
| EP-1323827-A2 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-4973354-A | AGRICULTURE, OPTICAL ISOMERS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | HACL2, APEH, HAO2 | SLC6A2 4872/4885SLC6A4 4805/4885SMN1; SMN2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.